Sugi Predict

Sugi Predict / Compounds / SCHEMBL1722210

SCHEMBL1722210

SCHEMBL1722210

CCOC(=O)c1cc(Oc2cnc(N)cn2)c2cn(CC)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCK P35557 8/20 0.43
▸ JMJD6 Q6NYC1 2/20 0.38
▸ MAPT P10636 3/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ CA14 Q9ULX7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1722819 0.85 GCK (0.52) GCKMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL1727457 0.85 GCK (0.55) GCK
SCHEMBL1722199 0.84 GCK (0.53) GCK
SCHEMBL1723440 0.83 GCK (0.46) GCKJMJD6MAPTSMN1; SMN2NPC1
SCHEMBL1722063 0.83 GCK (0.49) GCKJMJD6MAPTCYP1A2CYP2D6
SCHEMBL12040302 0.82 GCK (0.40) GCKJMJD6MAPTSMN1; SMN2NPC1
SCHEMBL1724799 0.80 HSD17B2 (0.47) GCKJMJD6MAPTSMN1; SMN2NPC1
SCHEMBL1725087 0.77 GCK (0.56) GCKPOLB
SCHEMBL1722669 0.76 GCK (0.40) GCKMAPTNPC1NPSR1ALDH1A1
SCHEMBL1724132 0.76 CYP2C19 (0.50) JMJD6MAPTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406230-A1 SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS Pfizer Inc. (US) 2012-01-18 — — EP disclosed
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators CORBETT JEFFREY W (US) 2011-12-29 — — US disclosed
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators CORBETT JEFFREY W (US) 2011-12-29 — — US disclosed
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators CORBETT JEFFREY W (US) 2011-12-29 — — US disclosed
WO-2010103438-A1 SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS PFIZER INC. (US) 2010-09-16 — — WO disclosed
WO-2010103438-A1 SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS PFIZER INC. (US) 2010-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators GCKR, GCK, GALK1 GCK 2/4885JMJD6 1798/4885MAPT 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.